TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92399

Peptide_Name

B5

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

LKKLFKKILKYLK-NH2

FASTA

>TPDB92399|Antibacterial;Anticancer;Toxicity|length=13
LKKLFKKILKYLK-NH2

Formula C84H147N19O15

Absent Amino Acids ARNDCEQGHMPSTWV

Common Amino Acids K

Mass 1663.21

PI 10.87

Basic Residues 6

Acidic Residues 0

Hydrophobic Residues 7

Net Charge +6

Boman Index 1.32

Hydrophobicity -0.169

Aliphatic Index 150.00

Half Life

Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 1490

Absorbance 280nm 89.59

Polar Residues 1

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

1

I

4

L

6

K

0

M

1

F

0

P

0

S

0

T

0

W

1

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 4 K: 6 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0

Length

13

Formula

C84H147N19O15

Mass

1663.21

PI

10.87

Net Charge

+6

Boman Index

1.32

Hydrophobicity

-0.169

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Analogue of BP 100

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 26.5 ± 1.5 µM

Detail Source Activity Anticancer

Activity Measurement 26.5

Target

Cancer Type Leukemia Cancer

Cell Line K-562

Tissue Affected Blood

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 27.3 ± 2.4 µM

Detail Source Activity Anticancer

Activity Measurement 27.3

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 28.2 ± 2.7 µM

Detail Source Activity Anticancer

Activity Measurement 28.2

Target

Cancer Type Breast Cancer

Cell Line MCF-7/ADM

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 28.3 ± 2.3 µM

Detail Source Activity Anticancer

Activity Measurement 28.3

Target

Cancer Type Leukemia Cancer

Cell Line K-562/ADM

Tissue Affected Blood

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2017